ARGENT BIOPHARMA LIMITED financials
ARGENT BIOPHARMA LIMITED
213800HRE3FQJ6RK4H10 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Cost of sales | A$687.4K | A$1.9M |
| Gross profit | A$203.7K | A$1.5M |
| Other income | A$728.0K | A$555.5K |
| Administrative expenses | A$15.6M | A$13.3M |
| Operating expenses | A$1.1M | A$879.2K |
| Operating profit (EBIT) | -A$16.7M | -A$19.9M |
| Finance costs | A$482.5K | A$262.3K |
| Profit before tax | -A$17.5M | -A$21.1M |
| Income tax expense | A$0 | A$2.0K |
| Profit for the year | -A$17.5M | -A$21.1M |
| — attributable to owners | -A$17.5M | -A$20.8M |
| — attributable to NCI | -A$17.8K | -A$310.0K |
| Total comprehensive income | -A$18.0M | -A$19.9M |
| Cash flow statement | ||
| Net cash from operating activities | -A$14.7M | -A$12.0M |
| Net cash from investing activities | -A$140.1K | A$606.2K |
| Purchase of PP&E (capex) | A$140.1K | A$189.9K |
| Net cash from financing activities | A$15.3M | A$9.7M |
| Proceeds from borrowings | A$0 | A$6.9M |
| Repayments of borrowings | A$0 | -A$216.3K |
| Lease liability payments | A$238.7K | A$201.0K |
| Net change in cash | A$463.7K | -A$1.6M |
| Balance sheet | ||
| Total assets | A$10.8M | A$10.0M |
| Non-current assets | A$8.0M | A$7.5M |
| Property, plant & equipment | A$5.7M | A$6.9M |
| Right-of-use assets | A$1.1M | A$588.7K |
| Current assets | A$2.7M | A$2.5M |
| Inventories | A$875.1K | A$1.4M |
| Trade & other receivables | A$476.5K | A$531.3K |
| Cash & equivalents | A$702.9K | A$239.8K |
| Total equity | -A$5.8M | -A$8.0M |
| — attributable to owners | -A$5.2M | -A$7.4M |
| Non-controlling interests | -A$672.4K | -A$628.8K |
| Non-current liabilities | A$4.4M | A$4.7M |
| Lease liabilities (non-current) | A$820.9K | A$384.6K |
| Current liabilities | A$12.2M | A$13.3M |
| Lease liabilities (current) | A$223.8K | A$190.6K |
| Trade & other payables | A$2.7M | A$3.3M |
| Derived metrics | ||
| Free cash flow | -A$14.8M | -A$12.2M |
| Operating margin | -1874.2% | -586.6% |
| Net margin | -1969.3% | -623.9% |
| Return on equity | 301.3% | 263.1% |
| Cash conversion ratio | 0.84× | 0.57× |
| Capex coverage | -104.64× | -63.12× |
| Other reported items | ||
| Comprehensive Income Attributable To Noncontrolling Interests | -A$62.1K | A$28.9K |
| Comprehensive Income Attributable To Owners of Parent | -A$17.9M | -A$19.9M |
| Current Financial Liabilities At Fair Value Through Profit Or Loss | A$8.7M | A$9.2M |
| Current Government Grants | A$553.6K | A$658.1K |
| Current Prepayments | A$685.7K | A$396.9K |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -A$658 | A$0 |
| Finance Costs Paid Classified As Operating Activities | A$3.1K | A$257.4K |
| Finance Income | A$1.9K | A$240 |
| Finance Income Received Classified As Operating Activities | A$0 | A$240 |
| Gains Losses On Exchange Differences On Translation Net of Tax | -A$431.3K | A$1.3M |
| Impairment Loss Impairment Gain and Reversal of Impairment Loss Determined In Accordance With IFRS9 | -A$1.3M | A$4.5M |
| Increase Decrease In Fair Value Measurement Liabilities | A$0 | -A$131.4K |
| Increase Decrease Through Acquisition of Subsidiary | — | A$1.2M |
| Increase Decrease Through Exercise of Options | — | A$0 |
| Increase Decrease Through Sharebased Payment Transactions | A$188.0K | A$1.3M |
| Investment Accounted For Using Equity Method | A$1.3M | A$0 |
| Issue of Convertible Instruments | A$500.0K | — |
| Issue of Equity | A$19.1M | A$2.8M |
| Issued Capital | A$123.3M | A$103.7M |
| Liabilities | A$16.6M | A$18.0M |
| Miscellaneous Other Operating Income | A$56.3K | A$218.6K |
| Net Assets Liabilities | -A$5.8M | -A$8.0M |
| Noncurrent Government Grants | A$3.6M | A$4.3M |
| Noncurrent Provisions | A$16.8K | A$21.0K |
| Other Comprehensive Income | -A$431.3K | A$1.3M |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | -A$431.3K | A$1.3M |
| Other Expense By Function | A$424.0K | A$1.2M |
| Proceeds From Government Grants Classified As Investing Activities | A$0 | A$796.1K |
| Research and Development Expense | A$2.3M | A$3.0M |
| Reserve of Exchange Differences On Translation | -A$71.5K | A$315.4K |
| Reserve of Sharebased Payments | A$1.3M | A$8.1M |
| Retained Earnings | -A$129.7M | -A$119.2M |
| Revenue From Contracts With Customers | A$891.1K | A$3.4M |
Every line item above is a fact tagged in ARGENT BIOPHARMA LIMITED's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (AUD), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.